中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (20) :1591-1596    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
CYP3A5*3��MDR1 G2677T/A�����̬�Զ�����ֲ���߻�����AѪҩŨ�ȼ���Ч��Ӱ��
л��1,2���κ���1a*�����컪1b����˳��1b��̷����1b
1.�Ͼ�����������ҽԺ��a.ҩѧ�ƣ�b.������ƣ����� 350025��2.����ҩ�ƴ�ѧҩѧԺ������ 110016
XIE Yu1,2��SONG Hong-tao1a*��WANG Qing-hua1b��YANG Shun-liang1b��TAN Jian-ming1b
1.Fuzhou General Hospital of Nanjing Military Region��a. Department of Pharmacy��b. Department of Urology��Fuzhou 350025��China��2. School of Pharmacy��Shenyang Pharmaceutical University��Shenyang 110016��China��Fuzhou 350025��China

Download: PDF (1264KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �о�CYP3A5*3��MDR1 G2677T/A����ͻ�������ֲ�����߷��û�����AŨ��/��������������C/D�䣩��������Ӧ�ͼ����ųⷴӦ��Ӱ�졣���� ���þۺ�ø����Ӧ��PCR��������������Ƭ�γ��ȶ�̬�ԣ�RFLP���������141������ֲ����CYP3A5*3��MDR1 G2677T/A�����ͣ��Ƚϲ�ͬ�����ͻ���֮�价����A��C/D��ֵ��������Ӧ�ͼ����ųⷴӦ�����ʵIJ��졣��� CYP3A5*1/*1��CYP3A5*1/*3��������7��14��30 d��C0/D��ֵ���Ե���CYP3A5*3/*3�ͻ���(P<0.01)����䲻����Ӧ�ͼ����ųⷴӦ������ȴ�������Բ���(P>0.05)��MDR1 2677λ��Ұ����(GG)��ͻ���Ӻ���(GT��GA)��ͻ�䴿����(TT��AA��AT)3������ͻ�������7��14��30 d��C0/D��ֵ��7��30 d��C2/D��ֵ���������Բ���(P<0.05)��ͻ����C/D��ֵ����Ұ���ͣ�3�����ڵļ����ųⷴӦ�����ʵ���Ұ����(P<0.05)����䲻����Ӧ�������������Բ���(P>0.05)������ CYP3A5*3��MDR1 G2677T/A�����̬����C/D��ֵ������أ���MDR1 G2677T/A������ֲ���ߵļ����ųⷴӦ������ϵ����ҩǰ������ֻ����������ڻ�����A�ĸ��廯��ҩ��
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� ����ֲ   ������A   ϸ��ɫ��P450 3A5ø   MDR1 G2677T/A   �����̬��     
Abstract�� OBJECTIVE To investigate the effects of CYP3A5*3 and MDR1 G2677T/A on concentration/dosage*body surface area ratio (C/D��) and adverse effects of cyclosporine and acute rejection in renal transplant patients. METHODS The CYP3A5*3 and MDR1 G2677T/A genotypes of 141 renal transplant patients treated with cyclosporine were determined by PCR-RFLP method. The differences in C/D�� ratios, adverse reactions and acute rejection were compared among all of the genotype groups. RESULTS The C0/D�� ratios of CYP3A5*1/*1 and CYP3A5*1/*3 carriers were significantly lower than those of CYP3A5*3/*3 patients on 7th, 14th and 30th day after renal transplantation, while no significant difference was observed in adverse effects and acute rejection among different genotypes. The C/D�� ratios of three MDR1 G2677T/A genotypes showed significant difference on 7th, 14th and 30th day after renal transplantation except C2/D�� ratios on 14th day. The wild-type (G/G) had lower C/D�� ratios than mutant. The acute rejection incidenc showed significant difference among the three groups in three months without significant difference in adverse effects. CONCLUSION CYP3A5*3 and MDR1 G2677T/A are correlated with C/D�� ratios in renal transplant patients, and the incidence of acute rejection in the three groups of MDR1 G2677T/A genotypes is significantly different. Clinical application of pharmacogenetic studies will be helpful for the individualization of cyclosporine dosage.
Keywords�� renal transplantation,   cyclosporine,   CYP3A5,   MDR1 G2677T/A     
�ո�����: 2011-11-11;
���ñ���:   
.CYP3A5*3��MDR1 G2677T/A�����̬�Զ�����ֲ���߻�����AѪҩŨ�ȼ���Ч��Ӱ��[J]  �й�ҩѧ��־, 2011,V46(20): 1591-1596
.Effects of CYP3A5*3 and MDR1 G2677T/A Genetic Polymorphism on Concentration and Efficacy of Cyclosporin in Renal Transplant Patients[J]  Chinese Pharmaceutical Journal, 2011,V46(20): 1591-1596
��
[1] TANABE M��IEIRI I��NAGATA N��et al. Expression of P-glycoprotein in human placenta�� Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene [J]. J Pharmacol Exp Ther��2001��297(3)��1137-1143. [2] TU X D��JIANG Q H��LAN F H. Comparison of three sample methods for genomic DNA extraction [J]. Chin J Lab Diagn(�й�ʵ�����ѧ)��2006��10(3)��264-266. [3] LOWN K S��MAYO R R��LECHTMAN A B��et al. Role of intestinal P-glycoprotein(mdr1) in interpatient variation in the oral bioavailability of cyclosporine[J]. Clin Pharmacol Ther��1997�� 62(3)��248-260. [4] KUEHL P��ZHANG J��LIN Y��et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J]. Nat Genet��2001��27(4)��383-391. [5] ROY J N��LAJOIE J��ZIJENAH L S��et al. CYP3A5 genetic polymorphisms in different ethnic populations[J]. Drug Metab Dispos��2005��33(7)��884-887. [6] ZHU B��CHEN G I��CHEN X P��et al. Genotype of CYP 3AP1 associated with CYP3A activity in Chinese Han population [J]. Acta Pharmacol Sin���й�ҩ��ѧ������2002��23(6)��567-572. [7] YATES C R��ZHANG W��SONG P��et al. The effect of CYP3A5 and MDR1polymorphic expression on cyclosporine oral disposition in renal transplant patients[J]. J Clin Pharmacol��2003��43(6)��555. [8] MAI I��PERLOFF E S��BAUER S��et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients[J]. Br J Clin Pharmacol��2004��58(5)��548-553. [9] SINGH R��KESARWANI P��SRIVASTAVA A��et al. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India[J]. Arch Med Res��2008��39(7)��695-701. [10] WANG Y��WANG C��LI J��et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem[J]. Eur J Clin Pharmacol��2009��65(3)��239-247. [11] QIU X Y��XIAO Z��ZHONG L J��et al. Influence of MDR1 genetic polymorphisms on ciclosporin pharmacokinetics in Chinese renal transplant patients[J]. Chin J Clin Pharm(�й��ٴ�ҩѧ��־)��2008��17(3)��141-147.
[1] ������ ��÷ ����Ӣ.�ຣ��������ȺCYP2C19�����̬���о�[J]. �й�ҩѧ��־, 2012,47(7): 539-542
[2] ��ٻ ���� ��ӱ ��һ�� .ת�˵��׻����̬��������ͪ�ֲ���������о�[J]. �й�ҩѧ��־, 2012,47(6): 454-457
[3] Ф���� ���� ��� ƽ���� ��־�� .������A��������֬��������Ʊ�������[J]. �й�ҩѧ��־, 2012,47(5): 362-366
[4] ���� ���� ����ͬ ���� ����� ����Ƽ.�й���ȺSTX4�����̬�ԶԻ�����Ӧ�ü�����Ӱ��[J]. �й�ҩѧ��־, 2011,46(9): 691-694
[5] ��� ¬����.�����̬�Զ�������ֲ���������Ƽ���ЧӰ����о���չ[J]. �й�ҩѧ��־, 2011,46(8): 561-564
[6] ��� ��� ������ ��ܿ .CYP3A5�����̬�Զ��ٴ�ҩ������ѧӰ����о���չ[J]. �й�ҩѧ��־, 2011,46(20): 1541-1545
[7] Ϳ���� ���Ҽ� ��˼Դ ʯ���� ����Ƽ ���� �����.�ȶ�������л�������ת����1��ϸ��ģ�͹���[J]. �й�ҩѧ��־, 2011,46(20): 1546-1551
[8] ������ ���� ���� �Ų� ���.����CYP3A5��MDR1�����̬�������ֲ������������Ī˾�ĸ��廯��ҩ������о�[J]. �й�ҩѧ��־, 2011,46(17): 1366-1369
[9] ������ ���� ���� ���� ����÷ ������ ���� ������.���ӱ����Ƽ�������ֲ��������ù������ѪҩŨ�ȵ�Ӱ��[J]. �й�ҩѧ��־, 2011,46(16): 1273-1275
[10] ����÷ ���� ���� ���� ������.ARCHITECT��TDx�ⶨ������AѪҩŨ��������о�[J]. �й�ҩѧ��־, 2011,46(13): 1020-1022
[11] ����Զ л�� �κ���.������˥��ҩ�������ѧ�о���չ[J]. �й�ҩѧ��־, 2011,46(11): 804-808
[12] ����Ƽ ���� ���� ���� �ܺ��.����������ת����1��ҩ��������о���չ[J]. �й�ҩѧ��־, 2011,46(11): 801-803
[13] ��ٻ ���� ��ӱ ������ ��һ��.���ٰ���ҩ����BCRP��λ�������й����彡����Ⱥ�еķֲ�[J]. �й�ҩѧ��־, 2011,46(10): 771-773
[14] ��С�� ��ǿ ����.�����ۺ������ߵĻ�����AѪҩŨ��Ӱ�����ط���[J]. �й�ҩѧ��־, 2010,45(9): 686-689
[15] ���� �Զ��� ��ȫ�� ������ ������ ������ Ԭ����.MDR1�����̬�ԶԸ��ƻ��߷�̫�ᾲ����ʹҩЧѧ��Ӱ��[J]. �й�ҩѧ��־, 2010,45(5): 379-380
Copyright 2010 by �й�ҩѧ��־